Serum lipids and glucose abnormalities in HIV/AIDS patients on antiretroviral therapies

West African Journal of Medicine

Volumn 28, Issue 1, 2009, Pages 10-15

  Salami, A K ^a,b   Akande, A A ^a   Olokoba, A B ^a  

^a UNIVERSITY OF ILORIN   (Nigeria)

^b NONE   (Nigeria)

Author keywords

AIDS; Antiretroviral therapy; Dysglycaemia; Dyslipidaemia; HIV; Nigeria

Indexed keywords

EFAVIRENZ; GLUCOSE; INDINAVIR; LAMIVUDINE; LIPID; NEVIRAPINE; RITONAVIR; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NIGERIA; PREVALENCE; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; AGED; BLOOD; COMPARATIVE STUDY; COMPLICATION; CONFIDENCE INTERVAL; DYSLIPIDEMIAS; EPIDEMIC; LIPID METABOLISM; METABOLISM; MIDDLE AGED; RISK; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; CHOLESTEROL, HDL; CONFIDENCE INTERVALS; DISEASE OUTBREAKS; DYSLIPIDEMIAS; FEMALE; GLUCOSE; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; NIGERIA; PREVALENCE; RISK; RISK FACTORS; YOUNG ADULT;

EID: 67650488456     PISSN: 0189160X     EISSN: None     Source Type: Journal    
DOI: 10.4314/wajm.v28i1.48417     Document Type: Article

References (25)

1. Salami AK, Olatunji PO, Fawibe EA. Influence of highly active anti-retroviral therapy (HAART) on the survival of HIV-infected patients: Part report of the Ilorin trial center. African Journal Clinical Experi-mental Microbiology 2005; 6: 34-39.
2. Hammer SM, Squires KE, Hughes MD, Grimmes JM, Demeter LM, Gurrier JS, et al. A control led trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-733. (Pubitemid 27417971)
3. Marschner IC, Collier AC, Coombs RW, D'Aquilla RT, De Gruttola V, Fischl MA. Use of changes in plasma levels of Human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998; 177: 40-47. (Pubitemid 28030432)
4. th edition, flying publisher 2006, pages 1-3. Available at http://www.hivmedicine.com/textbook/cr.htm
5. Dube MP, Stein JH, Aberg JA, Fitchtenbaum CJ, Gerber JG, Tashiman KT, et al. Guidelines for the evaluation and management of hyperlipidaemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37: 613-627 (Pubitemid 37100800)
6. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197. (Pubitemid 27274286)
7. Friis-Moller N, Sabin CA, Weber R, D'arminio Monforte A, EL- Sadr WM, Reiss P. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
8. Siedel J, Hagele EO, Ziegenhorn J. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075-1080.
9. Mcgowan MW, Artiss JD, Stranbargh DR. Perioxidase coupled method for the colorimetric determination of serum triglyceride. Clin Chem 1983; 29: 538-542. (Pubitemid 13160770)
10. Trinder P. Determination of blood glucose using 4-aminophenazone as oxygen acceptor. J Clin Path 1969; 22: 246.
11. Alberti KG, Zimmet PZ. Definition of diagnosis and classification of diabetes mellitus and its complications. PART 1. Definition and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
12. Salami AK, Olatunji PO, Oluboyo PO. Spectrum and prognostic significance of opportunistic diseases in HIV/AIDS patients in Ilorin, Nigeria. West Afr J Med 2006; 25: 52-56. (Pubitemid 43772823)
13. Second Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol (Adult Treatment Panel II). Circulation. 1994; 89: 1333-1445.
14. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Adda N, Rozenbaum W. Diabetes, insulin resistance and hyperlipidaemia in lipodystrophic HIV-infected patients on highly active anti-retroviral therapy (HAART). Diabetes Metab 1999; 25: 225-232. (Pubitemid 29426373)
15. Hertel J, Struthers H, Horj CB, Hruz PW. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem 2004; 279: 55147-55152 (Pubitemid 40066508)
16. Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis. 2007; 45: 111-119. (Pubitemid 46984626)
17. WHOPAR pARV4, summary of product characteristics; Stavudine Capsules 30mg/40mg (Ranbaxy) HA296/297. Uncommon: Development of diabetes mellitus. 2007, version 1.0 pages 5-9. Available at: http://www.who.int/prequal/WHOPAR/ WHOPARPRODUCTS/HA296PARV 4v1.pdf
18. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS. 1997;11: 938-939.
19. Roberts AD, Muesing RA, Parenti DM, Hsia J, Wasserman AG, Simon GL. Alterations in serum levels of lipid and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 29: 441-443. (Pubitemid 29380215)
20. Gallant JE, Staszewski S, Pozniak AL, Dejesus E, Sulleiman JM, Miller MD et al. Efficacy and safety of tenofovir vs. stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004; 292: 191-201. (Pubitemid 38917996)
21. Nunez M, Soriano V, Martin-Carbonero L, Barios A, Barrerio P, Blanco F, et al. (Spanish Efavirenz vs. Nevirapine Comparison (SENC) Trial: A Randomized, Open-Label Study in HIV-infected Naïve Individuals. HIV Clin Trials 2002; 3: 186-194
22. van Leth F, Phanuphak P, Stroes E, Gazzard B, Cahn P, Raffi F, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naïve patients infected with HIV-1. PLoS Med 2004; 1: e73 (Pubitemid 40412701)
23. Smith CJ, Levy I, Sabin CA, Kaya E, Johnson MA, Lipman MC. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med 2004; 5: 88-92. (Pubitemid 38404661)
24. The WHO guidelines on "Antiretroviral Therapy for HIV Infection in Adults and Adolescents" (2006 revision) . http://www.who.int/hiv/pub/ guidelines/ARVadultguidelines.pdf
25. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002; 16: 859-863. (Pubitemid 34409009)